# A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy

> **NCT02788123** · PHASE4 · TERMINATED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 9 (actual)

## Conditions studied

- NSAID-induced Gastropathy

## Interventions

- **DRUG:** bismuth tripotassium dicitrate
- **DRUG:** pantoprazole

## Key facts

- **NCT ID:** NCT02788123
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-03
- **Primary completion:** 2017-05-29
- **Final completion:** 2017-06-13
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Internal reassessment of the medicinal product development strategy by Sponsor
- **Last updated:** 2017-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02788123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02788123, "A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT02788123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*